|> Select your country|
Proof of Harmlessness
An international 3 year clinical study on the daily use of PHYTOSOYA® measured the effects on the endometrium (the internal lining of the uterus) and the breast.
The 305 women taking part in this clinical study had the following profile:
- aged between 45 and 65 years old,
- menopausal for at least two years,
- suffering from hot flushes.
The study consisted of evaluating the daily dosage of 70 mg of isoflavones provided by PHYTOSOYA® for 3 years.
STUDY ON THE ENDOMETRIUM
After 3 years of use, no increase in the thickness of the endometrium was observed.
These results suggest that the specific PHYTOSOYA® extract, providing a daily quantity of 70 mg of isoflavones, does not stimulate the endometrium.
PHYTOSOYA® presents the special characteristic of containing a soya extract rich in daidzein, for which the SAFETY of the endometrium has been clinically proven according to a methodology that concurs with the recommendations of European authorities.
STUDY ON THE BREAST
The results demonstrate that after 3 years of use of PHYTOSOYA®, no change in mammary density was observed.
These results suggest that the specific PHYTOSOYA® extract, providing a daily quantity of 70 mg of isoflavones, does not have any effect on the BREAST.
PHYTOSOYA® presents the special characteristic of containing a soya extract rich in daidzein, the SAFETY of which on the BREAST is clinically proven.
« The studies cited above may not be extrapolated to other soya extracts with different daidzein and genistine compositions.
The extract contained in the PHYTOSOYA® range was specifically developed and studied with Laboratoires Arkopharma in order to guarantee its SAFETY, for your WELLBEING. »
|Copyright 2013 - Arkopharma Laboratoires Pharmaceutiques
Contact us - Terms and conditions